Benchmark Initiates Coverage On Seelos Therapeutics with Speculative Buy Rating

Benchmark initiates coverage on Seelos Therapeutics (NASDAQ:SEEL) with a Speculative Buy rating.

Benzinga · 11/14/2019 13:35

Benchmark initiates coverage on Seelos Therapeutics (NASDAQ:SEEL) with a Speculative Buy rating.